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5 Large scale, high throughput, cystic ﬁbrosis screening using a new
kit for CFTR mutation detection
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Italy
Cystic ﬁbrosis (CF, OMIM 219700) is an autosomal recessive disorder caused by
the presence of mutations in both alleles of the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene.
Until now, more than 1,900 CFTR gene mutations have been described. The most
widespread mutation found is the c.1521_1523delCTT (p.Phe508del, F508del), with
a high relative frequency in different populations. The frequency of the DeltaF508
mutation is estimated to about 50% of all CFTR mutations in southern Europe and
up to 80−90% in the Northern European Countries. Other mutations typically have
a population frequency below 5 percent, or are speciﬁc in certain ethnic groups.
This project aims to analyze high number of consecutive anonymous newborn
blood spots, from Tuscany and Umbria, Italy, for the detection of the most frequent
mutations in the CFTR gene as well as the polythymidine and TG repeats of intron 9.
The qualitative, high throughput, screening is performed using the Devyser CFTR
Core Kit, based on PCR allele speciﬁc technology and capillary electrophoresis.
The method has been optimized for automated processing to ensure the accuracy
and the reliability of the results while minimizing the time and costs.
6 The difﬁculty of the diagnosis of cystic ﬁbrosis when a new
mutation is present
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Introduction: Cystic Fibrosis is the most common hereditary disease with auto-
somal recessive character in Caucasians. It is characterized by a mutation in the
transmembrane conductance regulator protein − CFTR − and its manifestations are
essentially respiratory and digestive.
Case report: Girl 3 years old, father and mother smokers; sister 5 years healthy.
First hospitalization from 2 to 4 months of age with acute Bronchiolitis with severe
distress. Since then multiple hospitalizations, medicated with 125mcg ﬂuticasone
12/12 h, salbutamol 100 mcg SOS and daily respiratory physiotherapy. Esophagus
contrasted X-ray and gastric pH monitoring normal, two sweat tests of 55 and
48mmol/L and chest X-ray with diffuse bilateral inﬁltrates. Kept persistent wheez-
ing and tachypnea with severe impact on the height-weight evolution. Oriented to
Pediatric Pulmonology in July 2010 (10 months), presenting perioral cyanosis, Sp
O2 75−80% and bilateral scattered crackles. Fecal elastase normal and pulmonary
CT with hypo dense bands at bases in relation to infectious complications and
impaction. CF molecular study was negative and Staphylococos aureus and Pseudo-
monas aeruginosa were detected in respiratory secretions. Given the persistence of
clinical symptoms, was performed extended molecular CF study. R75Q mutation in
heterozygosity and sequence variation c.3140−92C>T heterozygosity in the CFTR
gene were detected. Treatment was started with evident clinical improvement.
Comments: In this case we want to stress the importance of extended molecular
study of CFTR gene when there is a very suggestive clinic of Cystic Fibrosis, since
the basic molecular study detects only 80% of mutations.
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Objectives and Methods: We present how the diagnosis of CF was made in a
family initially through non-identical twins.
Twin 2 presented at 5 weeks with poor feeding, vomiting and offensive stools.
Follow-up found she had loose stools, chronic cough and failure to thrive.
Twin 1 was admitted at 7 weeks with respiratory distress and ventilated for 48 hours
secondary to a viral respiratory tract infection. She continued to have abnormal
stools and a persistent cough.
Failure to thrive blood and stool testing was normal.
Newborn screening IRT and faecal elastase were normal. Sweat tests were equiv-
ocal. CF genotyping eventually found 2 mutations: dF508− I1027T and TG12T5
compound heterozygotes.
Standard CF management including Creon was commenced at 4 months. They
are thriving and symptoms have settled, followed up by the CF team. Sweat tests
became positive at 2 yrs 3 months.
Their 7 year old brother had recurrent lower respiratory infections and abnormal
stools. Sweat test and faecal elastase was normal. Genetic testing showed a TG12T5
heterozygote. He responded well to CF treatment.
Their maternal half brother is 12 years old. He has respiratory symptoms, normal
stools and is thriving. IRT, sweat test and initial genetic testing are normal. Extended
screening is ongoing.
Their father has a chronic productive cough, positive sweat test and is a dF508-
I1027T heterozygote, under the care of the adult CF team.
Their mother is an asymptomatic TG12T5 heterozygote.
Discussion: Sometimes the diagnosis of CF is difﬁcult if tests are normal. Some
CF genes will cause atypical phenotypes. The diagnosis allows testing of family
members from which others may be diagnosed and treated.
8 The in cis effect of c.2562T>G and c.2657+5G>A CFTR splice
variants
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Cystic ﬁbrosis (CF) is caused by mutations in the CFTR gene, approximately 1,900
have been described and most are presumed to be pathogenic. A signiﬁcant fraction
of CF-causing mutations affects pre-mRNA splicing. The potential pathogenic
nature of many non-obvious splicing variants has been neglected.
Here, we aimed to provide insights on a new CFTR complex allele carrying the
coding SNP c.2562T>G (exon 15) and the splicing mutation c.2657+5G>A (intron
16) in cis, thus testing if c.2562T>G has an effect on CFTR splicing. We investigated
for the occurrence of abnormal splicing using an adequate in vitro minigene model
mimicking the in vivo situation. The splicing products were analysed both at the
RNA and protein levels. Our results show that the minigene carrying the c.2562T>G
SNP alone showed a similar behaviour, at the RNA and protein level, as that of a
WT minigene. A minigene carrying the c.2657+5G>A mutation alone, produced
three transcripts: a WT transcript, a transcript lacking exon 16 and a transcript
lacking both exons 15 and 16. Exon 16 skipping is the main aberrant transcript
resulting from this mutation. The double mutant (c.2562T>G and c.2657+5G>A)
produced the same transcripts as the single mutant c.2657+5G>A. According to
these in vitro data, the c.2562T>G SNP does not seem to have any splicing effect
and/or a functional impact on CFTR expression when occurring in cis with the
c.2657+5G>A splicing mutation.
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